Literature DB >> 9818046

Idiopathic pulmonary fibrosis: current concepts.

J H Ryu1, T V Colby, T E Hartman.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is generally defined as a progressive, fibrosing inflammatory disease of the lung parenchyma of unknown cause. It is characterized by slowly increasing dyspnea, diffuse interstitial lung infiltrates, restrictive lung dysfunction, and impaired gas exchange. Ultimately, it is fatal in most patients, and treatment options remain unsatisfactory. The advent of high-resolution computed tomography of the chest and modifications in the histopathologic classification of interstitial pneumonias have reshaped the concept of IPF. Although initially thought to be a relatively specific clinicopathologic entity, it seems likely that IPF as previously defined is a heterogeneous disorder consisting of several clinicopathologic entities with differing histopathologic patterns, clinical course, response to therapy, and prognosis. The most common histologic pattern in cases previously defined as IPF is usual interstitial pneumonia, which is associated with a median survival of less than 3 years. For accurate prognosis and optimal management of patients, the clinician should attempt to be as precise as possible in distinguishing various clinicopathologic entities that have been included under the clinical heading of IPF. In the future, we recommend that the use of the term "idiopathic pulmonary fibrosis" be restricted to patients with usual interstitial pneumonia and that clinicians recognize the fact that other idiopathic interstitial pneumonias do not have the same prognostic effect traditionally ascribed to IPF.

Entities:  

Mesh:

Year:  1998        PMID: 9818046     DOI: 10.4065/73.11.1085

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  34 in total

1.  Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis.

Authors:  N Kaminski; J D Allard; J F Pittet; F Zuo; M J Griffiths; D Morris; X Huang; D Sheppard; R A Heller
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 2.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Intravenous immunoglobulin and fibrosis.

Authors:  Vered Molina; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Fibroblasts from patients with idiopathic pulmonary fibrosis are resistant to cisplatin-induced cell death via enhanced CK2-dependent XRCC1 activity.

Authors:  Jintaek Im; Richard Seonghun Nho
Journal:  Apoptosis       Date:  2019-06       Impact factor: 4.677

5.  Lipidomics revealed idiopathic pulmonary fibrosis-induced hepatic lipid disorders corrected with treatment of baicalin in a murine model.

Authors:  Changfeng Hu; Yiqi Wang; Yongsheng Fan; Haichang Li; Chunyan Wang; Jida Zhang; Shuijuan Zhang; Xianlin Han; Chengping Wen
Journal:  AAPS J       Date:  2015-03-12       Impact factor: 4.009

6.  Advances in the management of idiopathic pulmonary fibrosis.

Authors:  Jay H Ryu; Craig E Daniels
Journal:  F1000 Med Rep       Date:  2010-04-12

7.  Evaluation of recently validated non- invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients.

Authors:  Maha K Ghanem; Hoda A Makhlouf; Gamal R Agmy; Hisham M K Imam; Doaa A Fouad
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

8.  Conserved CDR 3 region of T cell receptor BV gene in lymphocytes from bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis.

Authors:  N Shimizudani; H Murata; H Keino; S Kojo; H Nakamura; Y Morishima; T Sakamoto; M Ohtsuka; K Sekisawa; M Sumida; T Sumida; T Matsuoka
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

9.  Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia.

Authors:  C Jakubzick; E S Choi; S L Kunkel; H Evanoff; F J Martinez; R K Puri; K R Flaherty; G B Toews; T V Colby; E A Kazerooni; B H Gross; W D Travis; C M Hogaboam
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

10.  VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.

Authors:  Laszlo Farkas; Daniela Farkas; Kjetil Ask; Antje Möller; Jack Gauldie; Peter Margetts; Mark Inman; Martin Kolb
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.